STOCK TITAN

CANAQUEST MED CORP - $CANQF STOCK NEWS

Welcome to our dedicated page for CANAQUEST MED news (Ticker: $CANQF), a resource for investors and traders seeking the latest updates and insights on CANAQUEST MED stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CANAQUEST MED's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CANAQUEST MED's position in the market.

Rhea-AI Summary
The NHL Alumni Association (NHLAA), NEEKA Health Canada, and CanaQuest Medical Corp have formed a study partnership to investigate the efficacy of Mentanine® in reducing anxiety in former NHL players. NEEKA will lead the research on Mentanine®, a natural cannabidiol and essential fatty acid product, to evaluate its effectiveness in improving the quality of life. The study will be conducted by NEEKA's clinical research team led by Dr. Hunter Land, Chief Scientific Officer of NEEKA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.1%
Tags
partnership
-
Rhea-AI Summary
CanaQuest Medical Corp awarded European Cannabinoid Patent for Mentabinol®, a novel THC formulation to reduce cannabis-induced negative neuropsychiatric side-effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CanaQuest Medical Corp has been awarded the Best Global Medical Cannabinoid Development Company 2023 in the Healthcare and Pharmaceutical Awards by Global Health & Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
CANAQUEST MED CORP

OTC:CANQF

CANQF Rankings

CANQF Stock Data

2.54M
9.28M
53.91%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Mississauga

About CANQF

we are engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. this is an extension of our plan to commercialize our proprietary biosilo(r) algae cultivation system for the high volume, low cost production of pure contaminant-free algae biomass which is high in omega-3 fatty acids. we have engaged two canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of omega-3s derived from algae oil and extracts from cannabis oil. our research is focusing on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health.